The science of

Your genes can indicate the appropriate medication

Each patient's genetic profile affects the effectiveness of the drugs they receive by up to 80%.. There are cases of patients who experience severe side effects to a drug, while others experience none.

This approach allows doctors and researchers to more accurately predict which treatment is appropriate for each individual patient, as no two people and diseases are the same.

There is proven variation in clinical drug response between patients.

As defined by the etymology of the word Pharmacogenetics, it combines pharmacology (the study of how drugs work in the body) and genetics (the study of genes and their functions).

Pharmacogenetics studies and analyses the response of patients to medications by correlating their genetic polymorphisms (SNPs) with the metabolism, toxicity, or efficacy of a drug.

What does the evidence show​

We now know that patients with the same condition respond differently to the same treatment. The genetic profile of the patient plays an important role, which influences the effectiveness of the drugs they receive by up to 80%.

Source: Lauschke et al., Pharmacology & therapeutics, 2019

The side effects of a CNS medication are the most important reason for discontinuing it. 34% of these were caused by the patient’s genetic profile.

Source: Verbeurgt et al., Pharmacogenomics, 2014

Pharmacogenomics is predicted to become a routine procedure in the near future, a routine procedure for all patients before prescribing antidepressants. This is also the goal for the application of precision medicine in psychiatry as well.

Source: Nassan et al., Mayo Clinic Proceedings, 2016

In a recent study of 501 Greek patients that identified the genotypes of the three P450 enzymes, it was found that a high percentage of patients are expected to have poor or intermediate metabolism of drugs metabolized by one of the P450 enzymes: 39% for CYP2C9, 60% for CYP2C19, and 38% for CYP2D6. Similarly, more than 70% of patients are expected to experience intermediate or enhanced gene-drug interactions for a range of CNS drugs.

Source: Bothos et al., 2021